Department of Pharmacotherapy, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan.
Department of Pharmacotherapy, Graduate School of Biomedical and Health Sciences, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan.
Biochem Biophys Res Commun. 2014 Jun 20;449(1):132-4. doi: 10.1016/j.bbrc.2014.04.159. Epub 2014 May 9.
Obesity is associated with several diseases including diabetes, nonalcoholic steatohepatitis (NASH), hypertension, cardiovascular disease, and cancer. Therefore, anti-obesity drugs have the potential to prevent these diseases. In the present study, we demonstrated that flurbiprofen, a nonsteroidal anti-inflammatory drug (NSAID), exhibited therapeutic potency against obesity. Mice were fed a high-fat diet (HFD) for 6 months, followed by a normal-chow diet (NCD). The flurbiprofen treatment simultaneously administered. Although body weight was significantly decreased in flurbiprofen-treated mice, growth was not affected. Flurbiprofen also reduced the HFD-induced accumulation of visceral fat. Leptin resistance, which is characterized by insensitivity to the anti-obesity hormone leptin, is known to be involved in the development of obesity. We found that one of the possible mechanisms underlying the anti-obesity effects of flurbiprofen may have been mediated through the attenuation of leptin resistance, because the high circulating levels of leptin in HFD-fed mice were decreased in flurbiprofen-treated mice. Therefore, flurbiprofen may exhibit therapeutic potential against obesity by reducing leptin resistance.
肥胖与多种疾病相关，包括糖尿病、非酒精性脂肪性肝炎（NASH）、高血压、心血管疾病和癌症。因此，抗肥胖药物有可能预防这些疾病。在本研究中，我们证明了非甾体抗炎药（NSAID）氟比洛芬具有治疗肥胖的功效。将小鼠用高脂肪饮食（HFD）喂养 6 个月，然后用正常饮食（NCD）喂养。同时给予氟比洛芬治疗。虽然氟比洛芬治疗组小鼠的体重明显减轻，但生长不受影响。氟比洛芬还减少了 HFD 诱导的内脏脂肪堆积。瘦素抵抗是肥胖发展的一个特征，其表现为对瘦素这种抗肥胖激素不敏感。我们发现，氟比洛芬的抗肥胖作用的一种可能机制可能是通过减弱瘦素抵抗来介导的，因为 HFD 喂养的小鼠中循环高浓度的瘦素在氟比洛芬治疗组中降低了。因此，氟比洛芬可能通过降低瘦素抵抗来发挥治疗肥胖的潜力。
